Journals / Osmangazi Tıp Dergisi / 2019 / Cilt: 41 - Sayı: 4

Assessment of Bone Mineral Density in Psoriasis Patients without Arthritis

Artriti olmayan Psoriasis Hastalarinda Kemik Mineral Yoğunluğunun Değerlendirilmesi

Pages
353–359
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study shows that BMD of psoriasis patients is not different from healthy control group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, we aimed to investigate the bone mineral density (BMD) of psoriasis patients, compare with healthy control group, and to evaluate whether topical corticosteroids and systemic treatments affect BMD in psoriasis patients.
📊
Key Findings & Data:Forty psoriasis patients admitted to dermatology outpatient clinic and 36 healthy subjects were included in the study.
💡
Conclusion & Impact:This study shows that BMD of psoriasis patients is not different from healthy control group.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:kemik mineral yoğunluğu · osteoporoz · artrit

Abstract

In this study, we aimed to investigate the bone mineral density (BMD) of psoriasis patients, compare with healthy control group, and to evaluate whether topical corticosteroids and systemic treatments affect BMD in psoriasis patients. Forty psoriasis patients admitted to dermatology outpatient clinic and 36 healthy subjects were included in the study. Lumbar and femur BMD of patient and control groups were measured. No statistically significant difference was found with regard to BMD in psoriasis and healthy control groups. When we compare the L1-L4 scores, femur BMD, L1-L4 BMD, femur Z, spine Z, and values of the psoriasis patients who receiving topical and systemic treatments, we did not found statistically significant difference. Femur neck T score was significantly higher in the group receiving topical treatment than in the group receiving systemic treatment. There were not statistically significant difference between disease duration and severity. The L1-L4 scores, L1-L4 BMD, spine Z values did not differ significantly between nail involvement and non-nail involvement groups. But the femur neck, femur total and femur Z scores were significantly lower in the group with nail involvement than group without nail involvement. This study shows that BMD of psoriasis patients is not different from healthy control group.

Özet

Çalışmamızda eklem tutulumu olmayan psoriasis hastalarında kemik mineral yoğunluğunu (KMY) değerlendirilerek sağlıklı kontrol grubu ile karşılaştırmayı ve topikal kortikosteroid ve sistemik tedavi kullanımının KMY üzerine etkisini göstermeyi amaçladık. Çalışmaya hastanemiz dermatoloji polikliniğine başvuran 40 psoriasis hastası ve 36 sağlıklı gönüllü dahil edildi. Hasta ve kontrol grubunun lomber ve femur KMY ölçüldü. Psoriazis ve sağlıklı kontrol gruplarında KMY açısından istatistiksel olarak anlamlı bir fark bulunmadı. Topikal ve sistemik tedavi alan psoriasisli hastaların L1-L4 skorları, femur KMY, L1-L4 BMD, femur Z, omurga Z ve kalsiyum değerleri karşılaştırıldığında, istatistiksel olarak anlamlı fark bulunmadı. Topikal tedavi alan grupta femur boynu T skoru, sistemik tedavi alan gruba göre anlamlı olarak daha yüksekti. Hastalık süresi ve şiddeti arasında istatistiksel olarak anlamlı fark yoktu. L1-L4 skorları, L1-L4 BMD, omurga Z, kalsiyum değerleri, tırnak tutulumu ve tırnak tutulumu olmayan gruplar arasında anlamlı farklılık göstermedi. Ancak femur boynu, femur total ve femur Z skorları tırnak tutulumu olan grupta tırnak tutulumu olmayan gruba göre anlamlı olarak düşüktü.Bu çalışma psoriasisli hastalarında, KMY’nin sağlıklı kontrol grubundan farklı olmadığını göstermektedir.

🔖

Cite This Article

ŞAŞ, S., ERDOĞAN, H. K., BULUR, I. (2019). Assessment of Bone Mineral Density in Psoriasis Patients without Arthritis. Osmangazi Tıp Dergisi, Cilt: 41 - Sayı: 4, 353–359. https://ajindex.com/articles/287731

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010;24:23-30
  2. Dowlatshahi EA, van der Voort EA, Arends LR, et al. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2013;169:266-82
  3. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Burns DA et al. (eds). Textbook of Dermatology. Malden: Blackwell Science, 1998: 1589-649
  4. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheum 1998;25:1544-52
  5. Veale DJ. Newtherapies and new goals for psoriatic arthritis. Arthritis Rheum 2011;63:874-76
  6. Cassell S, Kavanaugh A. Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment. J Immune Based Ther Vaccines 2005;3:6-9
  7. Haroon M, Fitzgerald O. Pathogenetic overview of psoriatic disease. J Rheumatol Suppl 2012;89:7-10
  8. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31
  9. Matkovic V, Colachis SC, Ilich JZ. Osteoporosis: Its prevention and treatment. In: Braddom R, Buschbcher RM, Dumitru D. (eds). Physical Medicine and Rehabilitation. Philadelphia: WB Saunders Company, 1996: 851-76
  10. Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997;7:390-406
  11. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41
  12. Dreiher J, Weitzman D, Cohen AD. Psoriasis and osteoporosis: a sex-specific association? J Invest Dermatol. 2009;129:1643-9. 13.Millard TP, Antoniades L, Evans AV, et al. Bone Mineral density of patients with chronic plaque psoriasis. Clin Exp Dermatol. 2001;26:446-8
  13. DiGiovanna JJ, Sollitto RB, Abangan DL, et al. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 1995;131:1263-7. 15.McMullen EA, Irvine AD, Dolan OM, et al. The risk of osteoporosis in association with acitretin therapy. Br J Dermatol 1999;141:78
  14. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997; 24:1489-94
  15. Mazanec DJ, Grisanti JM. Drug-induced osteoporosis. Cleve Clin J Med 1989; 5